Policy & Regulation
ALK starts clinical trial of investigational treatment for peanut allergy
27 June 2022 -

Danish pharmaceutical company ALK-Abelló A/S (CPH:ALK-B) announced on Monday the start of Phase I clinical development of its investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.

Conducted in North America, the trial will assess the tolerability and safety of an up-dosing regimen with a once-daily peanut SLIT tablet.

This follows the successful completion of a feasibility study in late 2021, which confirmed that the same technology used in ALK's SLIT tablets for respiratory allergies was also suitable for use in the peanut SLIT tablet.

Approximately 100 adults, adolescents and children with a confirmed peanut allergy will participate in the trial, which is expected to involve up to 15 centres. The trial is scheduled to be completed in 2023.